Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...
A mid-stage trial of 4D Molecular Therapeutics gene therapy for ... plus a reduced need for injections into the eye with current therapy Eylea. On the strength of the results, 4DMT is planning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback